Adjunctive remifentanil infusion in deeply sedated and paralyzed ICU patients during fiberoptic bronchoscopy procedure: a prospective, randomized, controlled study

Hervé Quintard1*, Isabelle Pavlakovic1, Jean Mantz2 and Carole Ichai1

Abstract

Background: Even with an adequate pain assessment, critically ill patients under sedation experience pain during procedures in the intensive care unit (ICU). We evaluated the effects of adjunctive administration of Remifentanil, a short-acting drug, in deeply sedated patient on variation of Bispectral Index (BIS) during a fiberoptic bronchoscopy.

Methods: A prospective, randomized, blinded, placebo-controlled study was conducted in 18-bed ICU. Patients needing a tracheal fibroscopy under deep sedation (midazolam (0.1 mg/kg per hour) fentanyl (4 μg/kg per hour)) and neuromuscular blocking (atracurium 0.5 mg/kg) were included in the study. A continuous monitoring of BIS, arterial pressure, and heart rate were realized before, during, and after the fiberoptic exam. An adjunctive continuous placebo or Remifentanil infusion was started just before the fiberoptic exam with a target effect-site concentration of 4 ng/ml using a Base Primea pump.

Results: Mean arterial pressure and heart rates were comparable between the placebo and Remifentanil groups at all times of the procedure. We did not observe differences in the variation of BIS values between the two groups during procedure. We described no change in BIS values relative to the placebo group in this population.

Conclusions: In deeply sedated and paralyzed patients, receiving analgesic support based on a scale score an additional administration of short-acting analgesic drug, such as Remifentanil, seems not to be necessary for acute pain control.

Trial registration: NCT00162591.

Keywords: Pain, Intensive care, Bispectral index, Remifentanil

Background

Pain, as it relates to care procedures, such as tracheal suction, mobilization, or wound care, is common in critically ill patients [1]. As such, it may have a negative impact on patient comfort and can contribute to the development of posttraumatic stress disorder at intensive care discharge. The Behavioral Pain Scale (BPS), by evaluating facial expressions, upper limb movements, and compliance with mechanical ventilation, has been developed and validated to assess pain in mechanically ventilated, noncommunicating patients [2,3]. Units that have implemented such pain monitoring procedures in daily patient care have reported decreases in hospital stays and in the number of ventilation days [4]. Even in properly sedated patients, however, variations on BPS scores have been described during a short painful procedure [5]. This suggests the need to optimize procedural pain control. Unfortunately in some situations, such as administration of muscle relaxants, this clinical scale cannot be used. Data indicate that variations of the Bispectral Index (BIS), initially developed to monitor the depth of anesthesia in the operating room, may be of interest to reflect cortical arousal associated with a painful procedure in mechanically ventilated, sedated, paralyzed patients [6].
Remifentanil, a short-acting opioid, is a particularly interesting option for the treatment of procedural pain in critically ill patients, due to its rapid onset and duration of action and metabolism independent of hepatic and renal status [7-9]. However, few data are available about its use in short painful procedure in ICUs [10].

The purpose of this study was to evaluate the effects of an adjunctive administration of Remifentanil on BIS variations during a short, painful procedure, such as fiberoptic bronchoscopy, in deeply sedated, paralyzed, mechanically ventilated patients.

Methods
This single-center (surgical and medical ICU recruitment), prospective, randomized, blinded, placebo-controlled study was approved by the Ethics Committee of the CHU of Nice, France (n° 06.027, Chairperson R. Collomp) on August 11, 2006, and written, informed consent was obtained from the families of the patients. Our study followed the CONSORT recommendations concerning the report of randomized trials. Inclusion criteria were: mechanically ventilated patient under sedation for Acute Respiratory Distress Syndrome (ARDS) needing an endotracheal fiberoptic bronchoscopy with alveolar lavage with use of muscle relaxants. Exclusion criteria were: evolving intracranial disease (brain injury, brain tumor, abscess, stroke, or hemorrhage). The sedation protocol was the same for all patients, and consisted of intravenous midazolam (0.1 mg/kg per hour) and fentanyl (1.5 μg/kg per hour). Drugs were administered continuously and their administration rates adapted step by step, ±0.03 mg/kg/h for midazolam and ±0.3 μg/kg/h for fentanyl, to the patient’s needs in accordance with a standard protocol using the Sedation Agitation Scale (SAS) (Appendix) [11] and the Behavior Pain Scale (BPS) [5] before neuromuscular blocking. This strategy was in accordance with the 2007 French Society of Critical Care guidelines [12]. The SAS and BPS targets before neuromuscular blocking were 1 and 3 (T0), respectively. BIS values were continuously recorded using BIS-XP (software version 3.12), developed by Aspect Medical System®, and routine hemodynamic monitoring was performed with the Philips® Intellivue monitor. When the SAS and BPS goals were reached, BIS was continuously recorded for 15 minutes (LB0-15). Patients were unrestricted randomized, in a double-blinded fashion, into two groups: placebo or Remifentanil group. Then, a neuromuscular blocking agent (atrocurium 0.5 mg/kg) was injected in minutes to minimize nonspecific histamine release. Neuromuscular blocking agents were systematically used to optimize ventilation during procedure and for optimization of the fiberoptic bronchoscopy [13]. Train of Four (TOF) responses of the left and right orbicularis were recorded (C0-C10). At the same time (T1), either Remifentanil or the placebo was given at a target effect-site concentration of 4 ng/ml using a Base Primea pump (Fresenius-Vial®, Brezins, France). The concentration of 4 ng/ml was chosen in view of previous data showing that higher concentrations can be associated with hypotension and bradycardia [14-17]. Ten minutes later, the endotracheal fiberoptic bronchoscopic procedure was started (T2) (FB 0-FB 20). BIS was recorded until 10 minutes after the end of the procedure (T3) (PF 0-PF 10) (Figure 1).

All statistical analysis of data was performed by using StatView software. Results were calculated for groups of 20 patients, following a previous study [6], to obtain a 50 % decrease in the BIS value after tracheal suction in treated patients with a power of 80 % and α of 0.05. Results were expressed as mean (±SD), and all data were tested for normal distribution by the Kolmogorov-Smirnoff test. Differences between the pre-procedure and maximum BIS values for a given fiberoptic bronchoscopy were compared between the two groups by Student’s t test. BIS, heart rate (HR), invasive mean arterial pressure (MAP), SpO₂, and CO₂ for each time and changes of these parameters during the procedure were analyzed using an one-way (or two-way) ANOVA for repeated measures analysis.

Results and discussion
Demographic data
Forty patients presenting criteria for ARDS defined by the American-European consensus conference [18] were included in this study between January 2008 and January 2009. One patient was excluded because of missing data. No adverse effects related to Remifentanil infusion occurred. There were no differences in age, weight, height, gender, length of sedation, or median dose of midazolam
and fentanyl before procedure between the two groups (Table 1). All of the patients had SAS and BPS scores of 1 and 3, respectively, before the use of muscle relaxant. The overall agreement between BIS value and clinical sedation assessment made with SAS and BPS was evaluated. All the patients had deep level of sedation controlled by SAS and BPS before procedure but high BIS values (>60) were present in nine cases. BIS values decreased lower than 60 after the administration of atra- curium agent for all patients.

Physiologic recording
The median recording time during the procedure was 12 ± 4 min, with no difference between the groups. Heart rates and mean arterial pressure were comparable between the placebo and Remifentanil groups during fiberoptic bronchoscopy procedure (Figures 2 and 3). We observed no SpO2 and CO2 variations during procedure.

BIS recording
The mean BIS values before the fiberoptic bronchoscopy were not significantly different between the two groups: 36.2 ± 11.9 vs. 35.8 ± 10.9 (p > 0.05) (Table 2). Similarly, we observed no differences between the two groups in the variation of the BIS value during the procedure (Figure 4). Specifically, relative to the values determined before the procedure, neither BIS nor maximum BIS variation were different during the fiberoptic bronchoscopy, between the two groups (15 ± 14 and 12 ± 10; p > 0.05; Figure 5).

Discussion
We report in this study that adjunctive boluses of remifentanil are not necessary to prevent acute pain in deeply sedated patient.

Protocolized optimized sedation and pain control in the intensive care unit (ICU) can help to reduce duration of mechanical ventilation and length of stay in ICU and hospital by reducing drug consumption [4,19]. However, it could be not sufficient to provide an adequate analgesia during an acute painful care. Indeed, Payen et al. described a rising of BPS during procedure in patient under correct level of sedation [5]. Optimization of analgesic control, by adjunctive therapy
for example, could be needed to impair the risk of post-traumatic stress. Remifentanil, because of its pharmacologic properties could be a very interesting approach. This short-acting drug could protect the patient during procedure without increasing the risk of oversedation and consequences. In this study, we did not observe differences in the variation of BIS values, as a surrogate for analgesia evaluation, between the Remifentanil and placebo groups in mechanically ventilated, deeply sedated patients during a fiberoptic bronchoscopy. Moreover, BIS value did not change over time in both groups. We also do not observe significant difference between placebo and Remifentanil group according to PAM and heart rate. Heart rate is always higher in the placebo group than in the remifentanil one, which could be explained by direct chronotropic negative effect of Remifentanil. The absence of BIS variation observed during

|                      | Placebo | Remifentanil |
|----------------------|---------|--------------|
| BIS value before fiberoptic bronchoscopy | 36 ± 12 | 36 ± 11 |
| Maximum BIS value during procedure | 53 ± 8 | 54 ± 11 |
| BIS value post fiberoptic bronchoscopy | 42 ± 6 | 46 ± 9 |

Table 2 BIS monitoring (mean ± SD)

In particular, critically ill conditions, such as patients with brain trauma or respiratory failure, or for care procedure (fiberoptic bronchoscopy, tracheotomy...), neuromuscular blocking agents administration is recommended making the use of sedation scale scores, such as the Behavioral Pain Scale (BPS) [5], impossible.
Bispectral Index, developed initially to monitor depth of anesthesia in the operating room [13,20,21], could be an approach. In an experimental study of healthy volunteers, adjunctive opioids to volatile agents-based anesthesia increases clinical sedation but has no impact on BIS value. However, patients did not suffer from acute painful procedure [22]. In ICU, BIS use remains controversial because of the high level of variability of this parameter as described in our study (Figure 4), which led us to study the variation of this rather isolated value. Some authors have concluded that the most recent version of BIS—BIS XP—is useful in the ICU setting for assessing sedation [23], whereas others do not share this view [24]. The use of BIS monitoring to assess pain in our study could be criticized, but it was shown to be sensitive to nociceptive stimuli in critically ill, sedated patients [6,25]. Brocas et al. were able to blunt BIS variations by adding a bolus of a short-acting opioid to sedated patients before endotracheal suction. Other studies have described similar results with other opioids [17]. In accordance with these results, and with the proposition of French consensus on sedation in the ICU, we decided to use this device to evaluate the level of pain of our critically ill patients [12].

Conclusions
Our study shows that in deeply sedated patients receiving analgesic support based on a scale score, additional administration of short-acting analgesic drug, such as Remifentanil, does not seem to be necessary for acute pain control assessed by BIS variation. These data should be studied further in a population of patients who need less sedation.

Appendix
A.1. Riker sedation-agitation scale (SAS)
A.1.1. Score term descriptor
7 Dangerous Agitation Pulling at ET tube, trying to remove catheters, climbing over bedrail, striking at staff, thrashing side-to-side
6 Very Agitated Requiring restraint and frequent verbal reminding of limits, biting ETT
5 Agitated Anxious or physically agitated, calms to verbal instructions
4 Calm and Cooperative Calm, easily arousable, follows commands
3 Sedated Difficult to arouse but awakens to verbal stimuli or gentle shaking, follows simple commands but drifts off again
2 Very Sedated Aroused to physical stimuli but does not communicate or follow commands, may move spontaneously
1 Unarousable Minimal or no response to noxious stimuli, does not communicate or follow commands

Abbreviations
SAS: Sedation agitation scale; BPS: Behavioral pain scale; BIS: Bispectral index.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
No financial support.
Conflicts of interest: none of the authors has any conflict of interest.
Author details
1Intensive Care Unit, University Hospital, Nice, France. 2Anesthesiology Department, Beaujon Hospital, AP-HP, Paris, France.
Authors' contributions
HQ conceived the study and participated in its design, coordination, and drafted the manuscript. IP participated in acquisition of data. JM participated in its design, coordination, and helped to draft the manuscript. CI has given final approval of the version to be published.

Received: 20 January 2012 Accepted: 16 July 2012
Published: 16 July 2012

References
1. Kalfon P, Mimoz O, Auxquier P, Loundou A, Gauzit R, Lepape A, Laurens J, Garnier B, Potcher T, Maillefeud Y: Development and validation of a questionnaire for quantitative assessment of perceived discomforts in critically ill patients. Intensive Care Med; 2010.
2. Novaes MA, Knobel E, Bork AM, Pavao OF, Nogueira-Martins LA, Ferraz MB: Stressors in ICU: perception of the patient, relatives and health care team. Intensive Care Med 1999, 25(12):1421–1426.
3. Chanques G, Viel E, Constantijn JM, Jung B, de Lattre S, Carr J, Cise M, Lefrart JY, Jaber S: The measurement of pain in intensive care unit: comparison of 5 self-reported intensity scales. Pain 2010, 151(3):711–721.
4. Payen JF, Bosson JL, Chanques G, Mantz J, Labaree J: Pain assessment is associated with decreased duration of mechanical ventilation in the intensive care unit: a post Hoc analysis of the DOLOREA study. Anesthesiology 2009, 111(6):1308–1316.
5. Payen JF, Bru O, Bosson JL, Lagnatra A, Noel E, Deschaux I, Lavagne P, Jacquot C: Assessing pain in critically ill sedated patients by using a behavioral pain scale. Crit Care Med 2001, 29(12):2258–2263.
6. Brocas E, Dupont H, Paugam-Burtz C, Servin F, Mantz J, Desmonts JM: Bispectral index variations during tracheal suction in mechanically ventilated critically ill patients: effect of an alfentanil bolus. Intensive Care Med 2002, 28(2):211–213.
7. Breen D, Wilmer A, Bodenham A, Bach V, Bonde J, Kessler P, Albrecht S, Shahik S: Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment. Crit Care 2004, 8(1):R21–R30.
8. Battershill AJ, Keating GM: Remifentanil: a review of its analgesic and sedative use in the intensive care unit. Drugs 2006, 66(3):365–385.
9. Dershewitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL: Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology 1996, 84(4):812–820.
10. Casey E, Lane A, Kurikoske D, McGeary S, Hayes N, Phelan D, Buggy D: Bolus remifentanil for chest drain removal in ICU: a randomized double-blind comparison of three modes of analgesia in post-cardiac surgical patients. Intensive Care Med 2010, 36(6):1380–1385.
11. Riker RR, Picard JT, Fraser GL: Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. Crit Care Med 1999, 27(7):1325–1329.
12. Sauder P, Andreoletti M, Cambonie G, Capellier G, Feissel M, Gall O: Sédation et analgésie en réanimation[nouveau né exclu], Ann Fr Anesth Réanim 20084ème conférence de consensus commune: sédation et analgésie en réanimation; 2007.
13. Chastre J, Trouillet JL, Vuagnat A, Jou-Julliou ML, Clavelier H, Dombret MC, Gibert C: Nosocomial pneumonia in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998, 157(4 Pt 1):1165–1172.
14. Stevens JB, Wheatley L: Tracheal intubation in ambulatory surgery patients: using remifentanil and propofol without muscle relaxants. Anesth Analg 1998, 86(1):45–49.
15. McAtamney D, O’Hare R, Hughes D, Carabine U, Mirakhur R: Evaluation of remifentanil for control of haemodynamic response to tracheal intubation. Anaesthesia 1998, 53(12):1223–1227.
16. O’Hare R, McAtamney D, Mirakhur RK, Hughes D, Carabine U: Bolus dose remifentanil for control of haemodynamic response to tracheal intubation during rapid sequence induction of anaesthesia. Br J Anaesth 1999, 82(2):283–285.
17. Guignard B, Menigaux C, Dupont X, Fletcher D, Chauvin M: The effect of remifentanil on the bispectral index change and hemodynamic responses after orotracheal intubation. Anesth Analg 2000, 90(1):161–167.
18. Bernard GR, Antigna A, Briggs KL, Carlet J, Falke K, Hudson L, Lamry M, Legall JR, Morris A, Spragga P: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149(5 Pt 1):818–824.
19. Kress JP, Pohlman AS, O’Connor MF, Hall JB: Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000, 342(20):1471–1477.
20. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Amal JM, Perez D, Séguy-Janoy M, et al: Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010, 363(12):1107–1116.
21. Glass PS, Bloom M, Keanre L, Roscow C, Seibel P, Manberg P: Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane, and alfentanil in healthy volunteers. Anesthesiology 1997, 86(4):836–847.
22. Manyam SC, Gupta DK, Johnson KB, White JL, Pace NL, Westenskow DR, Egan TD: When is a bispectral index of 60 too low?: Rational processed electroencephalographic targets are dependent on the sedative-opioid ratio. Anesthesiology 2007, 106(3):472–483.
23. Karamchandani K, Rewari V, Trikha A, Batra RK: Bispectral index correlates well with Richmond agitation sedation scale in mechanically ventilated critically ill patients. J Anesth 2010, 24(3):394–398.
24. Weatherburn C, Endacott R, Tynan P, Bailey M: The impact of bispectral index monitoring on sedation administration in mechanically ventilated patients. Anaest Intensive Care 2007, 35(2):204–208.
25. Selgas C, Toussignant-Laflamme Y, Tanguay A, Bourgault P: Exploring the validity of the bispectral index, the Critical-Care Pain Observation Tool and vital signs for the detection of pain in sedated and mechanically ventilated critically ill adults: a pilot study. Intensive Crit Care Nurs 2011, 27(1):46–52.

doi:10.1186/2110-5820-2-29
Cite this article as: Quintard et al.: Adjunctive remifentanil infusion in deeply sedated and paralyzed ICU patients during fiberoptic bronchoscopy procedure: a prospective, randomized, controlled study. Annals of Intensive Care 2012 2:29.